This matched study included 1,648 patients in the semaglutide group and 1,649 in the placebo group from the SUSTAIN 6 trial, as well as 4,949 patients in the dulaglutide group and 4,952 in the placebo group from the REWIND trial
I am inclined to believe the SURMOUNT trials combined with real-world data following successful weight loss (before such meds were available): expect 5-15% of successful "losers" to maintain
Metabolism: Clinical and Experimental 2013:11991205
That range frequently provides a good balance of stability, target specificity, and ability to cross cell membranes or bind to receptors
Lincoff noted that this trial wasnt focused on weight management, where trials typically involve changes in diet and exercise and close monitoring, but instead models the way cardiovascular disease is treated in the real world. He also noted that not all of the participants got the highest dose of Wegovy in this study
At such times, it may be necessary to add insulin in combination with glimepiride or even use insulin monotherapy
